JP6929273B2 - 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 - Google Patents

角膜の混濁および瘢痕化の予防および治療のための組成物および方法 Download PDF

Info

Publication number
JP6929273B2
JP6929273B2 JP2018512858A JP2018512858A JP6929273B2 JP 6929273 B2 JP6929273 B2 JP 6929273B2 JP 2018512858 A JP2018512858 A JP 2018512858A JP 2018512858 A JP2018512858 A JP 2018512858A JP 6929273 B2 JP6929273 B2 JP 6929273B2
Authority
JP
Japan
Prior art keywords
hgf
composition
cornea
purified
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526412A5 (https=
JP2018526412A (ja
Inventor
スニル シャウハン
スニル シャウハン
レーザ ダナ
レーザ ダナ
Original Assignee
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド, ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド filed Critical ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
Publication of JP2018526412A publication Critical patent/JP2018526412A/ja
Publication of JP2018526412A5 publication Critical patent/JP2018526412A5/ja
Priority to JP2021130457A priority Critical patent/JP2021181472A/ja
Application granted granted Critical
Publication of JP6929273B2 publication Critical patent/JP6929273B2/ja
Priority to JP2023179927A priority patent/JP2023179739A/ja
Priority to JP2025157838A priority patent/JP2025181979A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2018512858A 2015-09-11 2016-09-09 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 Active JP6929273B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021130457A JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2023179927A JP2023179739A (ja) 2015-09-11 2023-10-19 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2025157838A JP2025181979A (ja) 2015-09-11 2025-09-24 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217611P 2015-09-11 2015-09-11
US62/217,611 2015-09-11
PCT/US2016/050945 WO2017044743A1 (en) 2015-09-11 2016-09-09 Compositions and methods for prevention and treatment of corneal haze and scarring

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130457A Division JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018526412A JP2018526412A (ja) 2018-09-13
JP2018526412A5 JP2018526412A5 (https=) 2019-10-17
JP6929273B2 true JP6929273B2 (ja) 2021-09-01

Family

ID=58240852

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018512858A Active JP6929273B2 (ja) 2015-09-11 2016-09-09 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2021130457A Pending JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2023179927A Pending JP2023179739A (ja) 2015-09-11 2023-10-19 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2025157838A Pending JP2025181979A (ja) 2015-09-11 2025-09-24 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021130457A Pending JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2023179927A Pending JP2023179739A (ja) 2015-09-11 2023-10-19 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2025157838A Pending JP2025181979A (ja) 2015-09-11 2025-09-24 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Country Status (7)

Country Link
US (4) US10449234B2 (https=)
EP (2) EP3347034B1 (https=)
JP (4) JP6929273B2 (https=)
AU (3) AU2016320905B2 (https=)
CA (1) CA2999511C (https=)
ES (1) ES2983338T3 (https=)
WO (1) WO2017044743A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999511C (en) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions and methods for prevention and treatment of corneal haze and scarring
WO2019155833A1 (ja) * 2018-02-07 2019-08-15 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
EP3863715A4 (en) * 2018-10-09 2022-08-24 The Board of Trustees of the Leland Stanford Junior University MODIFIED FIBROBLASTIC GROWTH FACTOR VARIANTS COMBINED WITH MODIFIED HEPATOCYTE GROWTH FACTOR VARIANTS FOR THERAPY
WO2020185689A1 (en) * 2019-03-08 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Multilayer drug delivery coating for contact lens
EP3962511A4 (en) * 2019-04-29 2023-01-18 The Board of Trustees of the Leland Stanford Junior University METHODS OF OCULAR TREATMENT USING A GENETICALLY MODIFIED HEPATOCYTE GROWTH FACTOR DIMERIC FRAGMENT
EP4574211A3 (en) 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
AU2745599A (en) 1998-03-05 1999-09-20 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
US20030148950A1 (en) * 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US8575099B2 (en) * 2006-04-20 2013-11-05 Osaka University Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
JP5093783B2 (ja) * 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
US20070167935A1 (en) * 2007-01-19 2007-07-19 Serdarevic Olivia N Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea
US9556248B2 (en) * 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
HRP20191711T1 (hr) 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
US8999938B2 (en) * 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2999511C (en) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions and methods for prevention and treatment of corneal haze and scarring

Also Published As

Publication number Publication date
EP3347034A4 (en) 2019-05-08
HK1258026A1 (en) 2019-11-01
EP4417259A3 (en) 2024-10-23
WO2017044743A1 (en) 2017-03-16
CA2999511C (en) 2024-01-23
US11759499B2 (en) 2023-09-19
US20180256685A1 (en) 2018-09-13
US20210299219A1 (en) 2021-09-30
JP2025181979A (ja) 2025-12-11
AU2021286438A1 (en) 2022-01-20
CA2999511A1 (en) 2017-03-16
JP2018526412A (ja) 2018-09-13
EP3347034B1 (en) 2024-05-29
AU2016320905A1 (en) 2018-04-05
JP2021181472A (ja) 2021-11-25
EP3347034A1 (en) 2018-07-18
EP3347034C0 (en) 2024-05-29
US10449234B2 (en) 2019-10-22
AU2021286438B2 (en) 2024-12-05
US20200121758A1 (en) 2020-04-23
AU2025201563A1 (en) 2025-03-27
JP2023179739A (ja) 2023-12-19
ES2983338T3 (es) 2024-10-22
EP4417259A2 (en) 2024-08-21
US20240123032A1 (en) 2024-04-18
AU2016320905B2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US11759499B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Huang et al. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model
JP2002515858A (ja) 角膜移植に起因する疾患を処置するための殺菌／浸透性増強（ｂｐｉ）タンパク質
Riau et al. Collagen-based artificial corneal scaffold with anti-infective capability for prevention of perioperative bacterial infections
JP7068706B2 (ja) 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤
US20180333460A1 (en) Goblet cell replacement therapy
WO2016060917A2 (en) Formulations for histatin therapeutics
US20180280478A1 (en) Activators of cxcr3 for the treatment of angiopathies of the eye
EP3402511B1 (en) Compositions and methods for treatment of ocular diseases
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
US9636299B2 (en) Method for treating diabetic retinopathy
CN118717959A (zh) Pedf多肽模拟物在眼表疾病中的用途
JPWO2001091779A1 (ja) 角膜創傷治療剤
HK1182955A (en) Buffered ophthalmic compositions and methods of use thereof
WO2001091779A1 (fr) Remedes contre les lesions corneennes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201125

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210810

R150 Certificate of patent or registration of utility model

Ref document number: 6929273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350